Streetbeat News

AMIX

Autonomix Medical Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

2.83

Mkt cap

7.3M

Volume

53K

High

3.09

P/E Ratio

-0.17

52-wk high

93.80

Low

2.81

Div yield

N/A

52-wk low

2.55

Autonomix Medical, Inc. has released its financial results for the third quarter of fiscal year 2025 and provided a corporate update. The company is conducting a proof-of-concept clinical trial for pain associated with pancreatic cancer, with topline data expected in the first half of 2025.

Portfolio Pulse from

February 13, 2025 | 1:15 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) has released a new CEO Corner segment featuring insights from the 43rd Annual J.P. Morgan Healthcare Conference and recent industry news.

Portfolio Pulse from

January 24, 2025 | 2:00 pm

Autonomix Medical, Inc. has finalized the design of its ASIC microchip for a sensing technology catheter, marking a significant milestone towards a U.S. pivotal trial in 2025. The company is advancing towards submitting an IDE for FDA approval.

Portfolio Pulse from

January 17, 2025 | 1:15 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Closing Bell Series on January 22, 2025. CEO Brad Hauser will provide a corporate overview and business outlook during the webcast.

Portfolio Pulse from

January 15, 2025 | 1:45 pm

Autonomix Medical, Inc. has been granted a U.S. patent for its catheter-based technology aimed at treating cancerous tumors and related pain. This adds to their growing patent portfolio, which includes over 80 issued patents. A preclinical study showed significant reductions in metastases and tumor mass.

Portfolio Pulse from

December 30, 2024 | 1:45 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) has released a new CEO Corner segment where CEO Brad Hauser discusses the company's progress and future plans. This update is available on the company's website.

Portfolio Pulse from

December 23, 2024 | 1:45 pm

Autonomix Medical, Inc. has successfully closed a $10 million underwritten public offering, including a partial exercise of the over-allotment option. This funding will support the company's focus on precision nerve-targeted treatments.

Portfolio Pulse from

November 25, 2024 | 9:15 pm

Autonomix Medical, Inc. has announced the pricing of a $9.0 million underwritten public offering, involving common stock units and pre-funded warrant units.

Portfolio Pulse from

November 22, 2024 | 2:30 pm

Autonomix Medical, Inc. reported its Q2 FY2025 financial results and provided a corporate update. The company is conducting a proof-of-concept clinical trial for pain associated with pancreatic cancer, showing promising preliminary results with 100% of the lead-in patient responder group ceasing opioid use 4-6 weeks post-procedure.

Portfolio Pulse from

November 11, 2024 | 1:15 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.